About one-third of moderate-to-severely affected people with hemophilia perceived declines in their daily functional abilities over a period of three to five years, a Dutch study found. While no strong risk factors for such declines were identified, patients more likely to be affected were those who were obese, had…

Passion motivates us and puts a fire in our belly to strive for something outside ourselves. Without a sense of purpose, we become less motivated to rise above our current situation and struggle to find a key ingredient to a happy life. As we strive to find our way,…

People with hemophilia may benefit from physiotherapy and rehabilitation programs intended to manage bleeding and joint disease (arthropathy), but more research is needed to better understand those programs — and their duration — that might be of most help, a review study says. The review, “Recent advances in musculoskeletal…

The U.S. Food and Drug Administration has approved new vial strengths for Octopharma’s hemophilia A therapy Nuwiq, which means patients will need fewer vials per treatment session. Octapharma USA said single-dose strengths of 2,500, 3,000 and 4,000 International Units will be available in the United States in September. The vials are already…

Meticulous planning is familiar to many of us in the hemophilia community. I’ve previously discussed how my family accommodates my husband Jared’s severe hemophilia B while planning ahead, whether it’s for travel or our future. For instance, preparing for trips and vacations involves a checklist; we…

I can still feel the sting of frustration as I replay that night at the recent National Conference for Women and Teens with hemophilia in Detroit. The conference was a place of empowerment — a chance to connect, learn, and share experiences with others who live with hemophilia…

Biogen and Sobi  announced that they will be presenting updated and long-term data on two approved hemophilia treatments, Eloctate  (marketed as Elocta in Europe) for hemophilia A, and Alprolix for hemophilia B, at the World Federation of Hemophilia (WFH)’s 2016 World Congress next week. Specifically, data from separate Phase 3 extension studies evaluating each treatment’s safety and…

Priscilla Oren, a member of the hemophilia community, recently shared her family’s history with me. Her son was a victim of the “hemophilia holocaust” in the 1980s. During that time, many people with hemophilia contracted HIV/AIDS and hepatitis from the factor products used to treat their bleeding…

For the second year, key pharmaceutical and academic leaders in hemophilia therapy development will gather at the Hemophilia Drug Development Summit — to be held in Boston Aug. 20–22 —to discuss and advance the next generation of safe and more effective therapies for bleeding disorders. The recent approval of  Genentech’s …